Expert Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoing scientific exchange Medical can communicate the science while also identifying unmet needs evidence gaps and perspectives from the field and bringing those insights
Cancer Drug Discovery
Fascinating Anecdotes of Oncology Medicine
In the last decade oncology has garnered the most drugs approved by the FDA among all therapeutic areas
The Future of Multi-Modality CDMOs
Integrating Small Molecules, Peptides, and Advanced Therapies
What is changing is not simply the number of modalities but the way pipelines are built A sponsor may have small molecules
Agentic AI in Clinical Research
Traditional analytics describe what has happened or predict what might occur Agentic systems go further they reason towards a goal
In Vivo Gene Therapy
Delivery vs Manufacturing Reality
In vivo gene therapy is technically advanced yet commercially immature While the science has advanced enough
Building the Connected Patient Journey
How Recruitment, Decentralization, and Real-Time Data Are Converging in U.S. Clinical Trials
The first change is accountability Recruitment cannot promise access that the protocol later makes difficult to deliver
Advancing Biopharmaceutical Innovation Through Cell Encapsulation and Biomimetic Therapeutic Systems
My interest in biopharmaceutical engineering began during my senior year as an undergraduate For my capstone project I worked on the encapsulation of bioactive ingredients from traditional Chinese medicine for controlled release which introduced me to biomaterials and drug delivery systems
CPHI Americas 2026: Where Strategic Partnerships, AI, and Advanced Manufacturing Are Shaping Pharma’s Future
CPHI Americas marks a fundamental shift in what a pharmaceutical industry event can be Weve moved toward a contentfirst experience that prioritises strategic learning and meaningful connections
Leadership Insights: 6thAnnual Rare & Genetic Kidney Disease Drug Development Summit
The most important shift I have seen is the move from phenotypefirst to genotypefirst thinking and that is changing everything from diagnosis to trial design Genetic testing is moving earlier in the workup particularly
Pharmacovigilance in the GLP-1 Era: Safety Surveillance Challenges for Obesity Medicines and Real-World Use
The rapid uptake of GLP therapies is pushing pharmacovigilance beyond traditional slower models built for smaller and more controlled treatment populations Obesity use is broader longerterm
